ALK and adenocarcinoma: In this study, sEVs were isolated from MPE fluid of four NSCLC patients, whose tumors were of adenocarcinoma histology and clinically validated to harbor EML4-ALK-fusion (PE002), KRAS-mutation (PE009), or mutations in the kinase domain of EGFR (PE011 and PE020) (Figure 4A, Table S3).